ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
ATARI trial tests the ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib in
patients with relapsed gynecological cancers to assess the response in groups of patients
selected based on their cancer cell subtype and the presence of an abnormality in ARID1A
gene.